key: cord-0985828-h7p4ofoi
authors: Massad, E.; Amaku, M.; Covas, D. T.; de azevedo Neto, R. S.; Coutinho, F. A. B.
title: Modelling the Impact of Delaying Vaccination Against SARS-CoV-2 Assuming Unlimited Vaccines Supply
date: 2021-02-23
journal: nan
DOI: 10.1101/2021.02.22.21252189
sha: c070c1bea6ba5e70f7cbaf333e60b00235132b35
doc_id: 985828
cord_uid: h7p4ofoi

Abstract Background At the moment we have more than 109 million cases and 2.4 million deaths around the world and vaccination represents the only hope to control the pandemic. Imperfections in planning vaccine acquisition and difficulties in implementing distribution among the population, however, have hampered the control of the virus so far. Methods We propose a new mathematical model to estimate the impact of vaccination delay against COVID-19 on the number of cases and deaths by the disease in Brazil. We apply the model to Brazil as a whole and to the State of Sao Paulo, the most affected by COVID-19 in Brazil. We simulated the model for the populations of the State of Sao Paulo and Brazil as a whole, varying the scenarios related to vaccine efficacy and compliance from the populations. Results The model projects that, in the absence of vaccination, almost 170 thousand deaths and more than 350 thousand deaths until the end of 2021 for Sao Paulo and Brazil, respectively. If in contrast, Sao Paulo and Brazil had enough vaccine supply and so started a vaccination campaign in January with the maximum vaccination rate, compliance and efficacy, they could have averted more than 112 thousand deaths and 127 thousand deaths, respectively. In addition, that for each month of delay the number of deaths increases monotonically in a logarithm fashion, for both the State of Sao Paulo and Brazil as a whole. Conclusions Our model shows that the current delay in the vaccination schedules that is observed in many countries has serious consequences in terms of mortality by the disease and should serve as an alert to health authorities to speed the process up such that the highest number of people to be immunized is reached in the shortest period of time.

As the world struggles to implement vaccination schemes against SARS-CoV-2, limited production of doses, imperfections in planning vaccine acquisition and difficulties in implementing distribution among the population, have hampered the control of the virus so far [1] . As of 18 February 2021, 188 million people have been vaccinated around the world, which represents less than 3% of the total. In Brazil, the total number of vaccinated people so far is, around 2.5% of the target population [2] . The world vaccination rate currently is less than 4 million doses per day, a very timid rate [3] .

Soit is no surprise that vaccination by itself has had so far little effect on the number of cases and deaths that continues to soar in many countries. At the moment we have more than 109 million cases and 2.4 million deaths around the world [4] .

Although previous pandemics have demonstrated that pharmaceutical interventions are less important than non-pharmaceutical intervention in controlling the infection, there is a growing body of evidences that this will not be the case with the vaccines against COVID-19 [5] [6] [7] [8] .

Immediately after the emergence of SARS-CoV-2 in China, many laboratories around the world started the development of more than 100 types of different vaccines, short-circuiting in less than one year the usual time frame of new vaccines development and testing, which normally would be around ten years, a remarkable tour of force [6] , [9] .

There is a wide range of covid-19 vaccines being developed [ However, in order to have significant impact on the course of the pandemic, safe and effective vaccines have to emerge in less time that it would take the affected populations to reach natural herd immunity because to wait to have herd natural immunity would be disastrous. Therefore, an unprecedented time-schedule to roll out any effective vaccine is urgently needed. Nevertheless, in many countries the vaccination is limited to certain individual groups and the distribution of enough doses for these individuals is very slow. We have at the moment only 188 million doses applied in 64 countries around the world [11] .

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

The model is an extension of the one presented in [15] and has the following variables: 1) Susceptible individuals, denoted S(t), which can either be vaccinated with rate ν, or acquire the infection with rate β. Susceptible are born with rate Λ and die by other causes with rate μ;

2) Vaccinated individuals, denoted V(t), which are transferred from the susceptible state with the vaccination rate ν. The vaccine is assumed to have efficacy q and a fraction w of the susceptible complies with the vaccination policy. Vaccinated individuals die by other causes with rate μ;

3) Failure to be immunized individuals, denoted FV(t). A fraction (1-q) of those vaccinated susceptible fail to be immunized, and can either acquire the infection with the same rate β as those non-vaccinated susceptible or die by other causes with rate μ; 4) Exposed individuals, denoted E(t), are those individuals who acquired the infection but are still in the stage that precedes either the overtly diseased patients or the asymptomatic individuals (see below). Exposed individuals can either progress to an asymptomatic stage with rate δ A , or to full-blown COVID-19 patients with rate δ I or die by other causes with rate μ. A fraction p E of those exposed are infective to susceptibles; 5) Asymptomatic (or pauci-symptomatic) individuals, denoted A(t), who progressed from the exposed and are, therefore, infected with SARS-CoV-2 but show no or very few symptoms.

Asymptomatic individuals can either die by natural causes or by the infection, with rates μ . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint and α A , respectively, or recover from the infection with rate γ A . A fraction p A of these asymptomatic individuals are infective to susceptible; 6) Infective individuals, denoted I(t), are those individuals infected with SARS-CoV-2 and who show the characteristic clinical signs and symptoms of COVID-19. Infective individuals can either die by natural causes or by the infection, with rates μ and α I , respectively, or recover from the infection with rate γ I , or progress to hospitalized (H(t))or critically ill stages (G(t)) (see below) with rates σ H and σ G , respectively; . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The model is described by the following set of equations:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint

The total number of cases, Cases, is given by:

The total number of deaths, Deaths due to COVID-19,is given by:

The total number of vaccinated individuals, Vaccinated, is given by:

CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) In figure 2 we show the time that it would take to reach herd immunity (70% of the population) as a function of the vaccination rate, ν. This is calculated, approximately (neglecting mortality) as:

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) 

In equation (6), T means time to reach herd immunity (HI). 

We simulated model (1) with the parameters as in Below we show the results of the numerical simulations of the model.

We fitted the model parameters simultaneously to the data of cumulative number of reported cases and deaths (figure 3) for Brazil until December 18, 2020. The fitting procedure is described in [16] , is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; 1 0 [17] .To estimate a 95% probability interval (shaded area in figure 3 ), we assumed a normal distribution for the contact rate with a standard deviation of 1.0%. This result can also be seen in Figure 5 in which we show the percentage of averted deaths until the end of the year as a function of the vaccination rate for vaccination starting from January until May.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint

and vaccine efficacy of 70%) was considered.

In figure 6 we show the results of the same simulation as in Figure 5 with several vaccination scenarios, varying compliance, efficacy and data of the starting of the campaign.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint show the simulation with a vaccination rate of 0.05 days -1 . This implies in that with this rate the country would take approximately one year to reach the herd immunity, assumed to be 70% of the population. In addition, this vaccination rate means 544 thousand vaccinations per day, provided that there would be enough vaccine supply to this schedule.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In figure 8 we show the same simulated scenarios as in Figure 7 with a vaccination rate ten times lower.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint

We fitted the model parameters simultaneously to the data of cumulative number of reported cases, deaths and the number of ICU patients (figure9) for the State of Sao Paulo until December 18, 2020.

The fitting procedure is described in [16] , [17] .To estimate a 95% probability interval (shaded area in figure 9 ), we assumed a normal distribution for the contact rate with a standard deviation of 1.0%.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint The results are qualitatively the same as in the simulation for Brazil as a whole but with magnitude proportional to the population size differences.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. In tables 2 and 3 we summarize our main results for one particular scenario maximizing the vaccination rate (0.1 days -1 ), compliance of the population (80%) and vaccine efficacy (90%), that is, . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

The copyright holder for this preprint this version posted February 23, 2021. for both the State of Sao Paulo and Brazil as a whole.

In this paper we present a theoretical exercise, represented by a model intended to estimate the impact of (perhaps inevitable) delay in starting vaccination against SARS-CoV-2, illustrated with the . CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) We assumed vaccination rates that simulates immunization of up to 70% of the whole country in 9 months, which may seem unfeasible but Brazil has a long tradition in mass vaccination campaigns [18] , managing to immunize more than 20 million people in a single day [19] . Therefore, the maximum vaccination scenario would be a real possibility, given the country experience in mass vaccination schedules adopted in the past. However, due to difficulties in vaccine acquisition, the number of available doses so far has been very low indeed [21] . At the time of writing, Brazil has vaccinated slightly above 2% of its population, way below the target of at least 70% to achieve the assumed herd immunity level.

The model has some important limitations worth mentioning, the most important is perhaps that it does not consider age-dependence in incidence of the infection and in the mortality rates. However, the model was intended to simulate a mass vaccination campaign that would include all age strata in a relatively short period of time. In addition, we considered only the original variant of the virus, which means that our results represent a lower bound in the number of cases and deaths due to vaccination delay. The current scenario of the pandemic, in which new variants of SARS-CoV-2 are emerging in some countries [20] should be considered in the simulation of future vaccination models, but there is not enough empirical evidence of the impact of these new variants as related to the vaccine efficacy.

In conclusion, our model shows that the current delay in the vaccination schedules, that is observed in many countries, has serious consequences in terms of mortality by the disease and should serve as an alert to health authorities to speed the process up such that the highest number of people to be immunized is reached in the shortest period of time.

This work was partially supported by LIM01-HFMUSP, CNPq, FAPESP and Fundação Butantan.

. CC-BY-NC-ND 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)

The copyright holder for this preprint this version posted February 23, 2021. ; https://doi.org/10.1101/2021.02.22.21252189 doi: medRxiv preprint

Medical evidence related to English population changes in the eighteenth century

Appolo's Arrow: The Profound and Enduring Impact of Coronavirus on the Way we Live

Risk in vaccine research and development quantified

Available: domlipa.ca/sites/default/files/Covid-Vaccines.pdf

Two complementary model-based methods for calculating the risk of international spreading of a novel virus from the outbreak epicentre. The case ofCOVID-19

Modelling the test, trace and quarantine strategy to control the COVID-19 epidemic in the state of Sao Paulo

Modelling the impact of contact tracing of symptomatic individuals on the COVID-19 epidemic

A model-based design of a vaccination strategy against rubella in a non-immunized community of Sao Paulo State